Cytotoxic crossmatch analysis before allo-SCT is a poor diagnostic tool for prediction of rejection.

• The predictive value of cytotoxic crossmatch analysis before allo-SCT remains unclear. We retrospectively analyzed the clinical impact of cytotoxic T- and B-cell crossmatch testing before allo-SCT between January 2000 and June 2005. Cytotoxic crossmatches were performed in 157 patients receiving stem cells from matched unrelated donors or an HLA-A, -B or -DRB1 allele mismatched graft. Ninety patients are still alive. Eleven patients rejected their grafts. One of 11 patients with rejection was positive in a T-cell crossmatch before allo-SCT and 4 of 11 in B-cell crossmatches. T-cell crossmatches showed a sensitivity of 9% and a specificity of 97% compared with 36 and 86% for B-cell crossmatches. Positive T- and/or B-crossmatch before SCT had no predictive value for survival in this study as compared with patients with a negative crossmatch. In conclusion, the pretransplant cytotoxic T- and/or B-crossmatch is a poor predictor of rejection after allo-SCT.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Immunology in the medical area (hsv//eng)

Keyword

Adolescent

Adult

Aged

B-Lymphocytes

immunology

Child

Child

Preschool

Female

Graft Rejection

immunology

Graft Survival

immunology

Histocompatibility Testing

Humans

Infant

Male

Middle Aged

Predictive Value of Tests

Retrospective Studies

Risk Factors

Stem Cell Transplantation

methods

T-Lymphocytes

immunology

Transplantation

Homologous

immunology

Publication and Content Type

ref (subject category)

art (subject category)